Influencia comportamental de la Oleiletanolamida en la dependencia al etanol : un modelo animal

Vista sencilla de ítem
dc.contributor.advisorGonzález-Cuevas, Gustavospa
dc.contributor.advisorQuevedo Buitrago, William Giovannispa
dc.contributor.authorBermúdez Ocampo, Juan Santiagospa
dc.contributor.cvlacBermúdez Ocampo, Juan Santiago [0001392096]spa
dc.contributor.orcidBermúdez Ocampo, Juan Santiago [0000000283657221]spa
dc.contributor.researchgateBermúdez Ocampo, Juan Santiago [Juan-Bermudez-28]spa
dc.contributor.researchgroupSustancias Psicoactivasspa
dc.date.accessioned2025-07-21T13:25:18Z
dc.date.available2025-07-21T13:25:18Z
dc.date.issued2025
dc.descriptionilustraciones, diagramasspa
dc.description.abstractEl Trastorno por Consumo de Alcohol es un grave problema de salud pública, responsable de al menos tres millones de muertes (alrededor del 5% de la totalidad) en todo el mundo cada año. Es importante destacar que las mujeres son más vulnerables a los efectos negativos a largo plazo del consumo de alcohol en comparación con los hombres. Enfoques farmacológicos potenciales que prometen el desarrollo de futuros medicamentos para tratar el TCA son las sustancias relacionadas con los cannabinoides. Curiosamente, la Oleoiletanolamida, un análogo del endocannabinoide Anandamida que se encuentra en niveles variables en hombres y mujeres, es una alternativa de medicamento potencial y más segura que el agonismo del CB1, vinculado a un mayor riesgo de adicción a las drogas. Este estudio se propuso investigar el papel de la OEA en la modulación de los comportamientos relacionados con el alcohol en ratas Wistar hembras. Específicamente, se probaron los efectos moduladores de la OEA (10 mg/kg, IP) en la recompensa del alcohol (medida en la Preferencia del Lugar Condicionado) y el comportamiento similar a la ansiedad (medido en el laberinto en cruz) en dos grupos de ratas (con historial o sin historial de administración de alcohol). La oleoiletanolamida es un novedoso modulador terapéutico prometedor de las conductas relacionadas con el alcohol en un modelo de rata hembra: revierte la recompensa del alcohol y la agresión relacionada con el alcohol sin cambios en la ansiedad (Texto tomado de la fuente).spa
dc.description.abstractAlcohol Use Disorder (AUD) is a serious public health issue, killing at least three million people (around 5% of all deaths) throughout the world each year. Importantly, women are more vulnerable to the long-term negative health effects of alcohol when compared to men. Potential pharmacological approaches with promise for future drug development in treating AUD are cannabinoid-related drug substances. Interestingly, Oleoylethanolamide (OEA), an analog of the endogenous cannabinoid anandamide (AEA) found in variable levels in men and women, is a potential and safer drug alternative to CB1 agonism, linked to a higher risk for drug addiction. This study set out to investigate the role of OEA in the modulation of alcohol-related behaviors in female Wistar rats. Specifically, the modulatory effects of OEA (10 mg/kg, IP) on alcohol reward (as measured in the Conditioned Place Preference) and anxiety-like behavior (as measured in the p-maze) were tested in two groups of rats (with a history or no history of alcohol administration). Oleoylethanolamide is a promising novel therapeutic modulator of alcohol-related behaviors in a female rat model: reverses alcohol reward and alcohol-related aggression with no changes in anxiety.eng
dc.description.degreelevelMaestríaspa
dc.description.degreenameMagíster en Toxicologíaspa
dc.description.methodsEste estudio se propuso investigar el papel de la OEA en la modulación de los comportamientos relacionados con el alcohol en ratas Wistar hembras. Específicamente, se probaron los efectos moduladores de la OEA (10 mg/kg, IP) en la recompensa del alcohol (medida en la Preferencia del Lugar Condicionado) y el comportamiento similar a la ansiedad (medido en el laberinto en cruz) en dos grupos de ratas (con historial o sin historial de administración de alcohol).spa
dc.description.researchareaSustancias psicoactivasspa
dc.format.extent68 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.instnameUniversidad Nacional de Colombiaspa
dc.identifier.reponameRepositorio Institucional Universidad Nacional de Colombiaspa
dc.identifier.repourlhttps://repositorio.unal.edu.co/spa
dc.identifier.urihttps://repositorio.unal.edu.co/handle/unal/88362
dc.language.isospaspa
dc.publisherUniversidad Nacional de Colombiaspa
dc.publisher.branchUniversidad Nacional de Colombia - Sede Bogotáspa
dc.publisher.facultyFacultad de Medicinaspa
dc.publisher.placeBogotá, Colombiaspa
dc.publisher.programBogotá - Medicina - Maestría en Toxicologíaspa
dc.relation.referencesAlcohol [Internet]. [citado 2022 mayo 16]. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/alcoholspa
dc.relation.referencesAlcohol - OPS/OMS | Organización Panamericana de la Salud [Internet]. [citado 2022 mayo 16]. Disponible en: https://www.paho.org/es/temas/alcoholspa
dc.relation.referencesDANE. (2020). Boletín Técnico Encuesta Nacional de Consumo de Sustancias. Ministerio de Justícia, 3, 1–34. Disponible en: https://www.dane.gov.co/files/investigaciones/boletines/encspa/bt-encspa-2019.pdfspa
dc.relation.referencesObservatorio de Drogas de Colombia. (2017). Reporte de Drogas de Colombia. http://www.odc.gov.co/spa
dc.relation.referencesZahr, N. M., & Pfefferbaum, A. (2017). Alcohol’s effects on the brain: Neuroimaging results in humans and animal models. Alcohol Research: Current Reviews, 38(2), 183–196.spa
dc.relation.referencesNational Institute on Alcohol Abuse and Alcoholism. (2022). Alcohol’s effects on the body. Citado el 2 de mayo de 2023, de https://www.niaaa.nih.gov/alcohols-effects-health/alcohols-effects-body.spa
dc.relation.referencesNHTSA. Manejar Bajo la Influencia del Alcohol [Internet]. [cited 2024 Feb 15]. Available from: https://www.nhtsa.gov/es/conducir-de-forma-riesgosa/manejar-bajo-la-influencia-del-alcoholspa
dc.relation.referencesCuadrado A, Crespo J. Hypertransaminasemia in patients with negative viral markers. Rev Española Enfermedades Dig. 2004;96(7):484–500.spa
dc.relation.referencesThe European Medicines Agency - EMA. (2006). Anexo I: Ficha técnica o resumen de las características del Epidiolex. Agencia Europea de Medicamentos, 1–33. https://www.ema.europa.eu/en/documents/product-information/zerbaxa-epar-product-information_es.pdfspa
dc.relation.referencesEgziabher, T. B. G., & Edwards, S. (2013). Anexo I: Ficha tecnica o resumen de las caracteristicas del Sativex. Africa’s Potential for the Ecological Intensification of Agriculture, 53(9), 1689–1699.spa
dc.relation.referencesFood and Drug Administration. (2017). DATA SHEET: Dronabinol. www.fda.gov/medwatch.spa
dc.relation.referencesAblin J, Ste-Marie PA, Schäfer M, Häuser W, Fitzcharles MA. Medical use of cannabis products: Lessons to be learned from Israel and Canada. Schmerz. 2016 Feb;30(1):3-13. doi: 10.1007/s00482-015-0083-4. PMID: 26767992.spa
dc.relation.referencesSloan ME, Gowin JL, Ramchandani VA, Hurd YL, Le B. Neuropharmacology The endocannabinoid system as a target for addiction treatment : Trials and tribulations. Neuropharmacology [Internet]. 2017;124:73–83. Disponible en: http://dx.doi.org/10.1016/j.neuropharm.2017.05.031spa
dc.relation.referencesBetty Wedman-St. Louis. Cannabis A Clinician’s Guide. Vol. 148. 2018. 148–162 p.spa
dc.relation.referencesMojarrad, M., Samet, JH., Cheng, DM., Winter MR., Saitz, R. (2014). Marijuana use and achievement of abstinence from alcohol and other drugs among people with substance dependence: a prospective cohort study. Drug and Alcohol Dependence, 142: 91–97.spa
dc.relation.referencesSiklos-Whillans J, Bacchus A, Manwell LA. A Scoping Review of the Use of Cannabis and Its Extracts as Potential Harm Reduction Strategies: Insights from Preclinical and Clinical Research. Int J Ment Health Addict. 2020;spa
dc.relation.referencesMetz, V. G., da Rosa, J. L. O., Rossato, D. R., Milanesi, L. H., Burger, M. E., & Pase, C. S. (2021). Cannabidiol prevents amphetamine relapse and modulates D1- and D2-receptor levels in mesocorticolimbic brain areas of rats. European Neuropsychopharmacology, 50, 23–33. https://doi.org/10.1016/j.euroneuro.2021.04.008spa
dc.relation.referencesCassaret, Doull. Fundamentos de Toxicologia. McGraw-Hill; 2005.spa
dc.relation.referencesChesworth R, Karl T. Cannabidiol (CBD) reduces cocaine-environment memory in mice. Pharmacol Biochem Behav [Internet]. 2020;199(August):173065. Disponible en: https://doi.org/10.1016/j.pbb.2020.173065spa
dc.relation.referencesMéndez-Díaz, Mónica, Romero Torres, Brenda M., Cortés Morelos, Jacqueline, Ruíz-Contreras, Alejandra E., & Prospéro García, Oscar. (2017). Neurobiología de las adicciones. Revista de la Facultad de Medicina (México), 60(1), 6-16. Citado el 16 de agosto de 2022, de http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0026-17422017000100006&lng=es&tlng=es.spa
dc.relation.referencesCalpe-López, C., Pilar García-Pardo, M., Aguilar, M. A. (2019). Cannabidiol treatment might promote resilience to cocaine and methamphetamine use disorders: A review of possible mechanisms. In Molecules (Vol. 24, Issue 14). MDPI AG. https://doi.org/10.3390/molecules24142583spa
dc.relation.referencesMock ED, Gagestein B, Stelt M Van Der. Progress in Lipid Research Anandamide and other N -acylethanolamines : A class of signaling lipids with therapeutic opportunities. Prog Lipid Res [Internet]. 2023;89(July 2022):101194. Disponible en: https://doi.org/10.1016/j.plipres.2022.101194spa
dc.relation.referencesBilbao A, Serrano A, Cippitelli A, Pavón FJ, Giuffrida A, Suárez J, García-Marchena N, Baixeras E, Gómez de Heras R, Orio L, Alén F, Ciccocioppo R, Cravatt BF, Parsons LH, Piomelli D, Rodríguez de Fonseca F. Role of the satiety factor oleoylethanolamide in alcoholism. Addict Biol. 2016 Jul;21(4):859-72. doi: 10.1111/adb.12276. Epub 2015 Jun 2. PMID: 26037332; PMCID: PMC4668242.spa
dc.relation.referencesThe British Psychological Society and The Royal College of Psychiatrists. ALCOHOL USE DISORDERS. The NICE guideline on diagnosis, assessment and management of harmful drinking and alcohol dependence. National Clinical Practice Guideline 115; 2011. DSM 5 Criteria for Substance Use Disorders [Internet]. [citado 2021 Apr 23]. Disponible en: https://www.verywellmind.com/dsm-5-criteria-for-substance-use-disorders-21926spa
dc.relation.referencesMark TL, Kassed CA, Vandivort-Warren R, Levit KR, Kranzler HR. Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. Drug Alcohol Depend. 2009;99(1–3):345–349. [PubMed: 18819759]spa
dc.relation.referencesKatzung Bertram G. Farmacología básica y clínica. 15a ed. McGraw-Hill; 2022.spa
dc.relation.referencesGoodman’s & Gilman’s. The Pharmacological Basis of Therapeutics. 13TH ed. McGraw Hill. New York; 2018. 1–1297 p.spa
dc.relation.referencesLewis R. Goldfrank, MD, Robert Kirstein M. GOLDFRANK’S TOXICOLOGIC EMERGENCIES. 11th editi. 2019.spa
dc.relation.referencesLieber CS. Susceptibility to alcohol-related liver injury. Alcohol Alcohol Suppl. 1994;2:315-26. PMID: 8974351.spa
dc.relation.referencesGitto S, Golfieri L, Caputo F, Grandi S, Andreone P. Multidisciplinary view of alcohol use disorder: From a psychiatric illness to a major liver disease. Biomolecules. 2016;6(1):1–12.spa
dc.relation.referencesSkinner MD, Lahmek P, Pham H, Aubin HJ. Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS One. 2014;9(2):e87366. [PubMed: 24520330]spa
dc.relation.referencesO’Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry. 1992;49(11):881–7. [PubMed: 1444726]spa
dc.relation.referencesVolpicelli JR, Alterman AI, Hayashida M, O’Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49(11):876–80. [PubMed: 1345133]spa
dc.relation.referencesDonovan D, Mattson ME, Cisler RA, Longabaugh R, Zweben A. Quality of Life as an Outcome Measure in Alcoholism. J Stud Alcohol. 2005; Supplement(s15):119–39.spa
dc.relation.referencesMark TL, Kassed CA, Vandivort-Warren R, Levit KR, Kranzler HR. Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. Drug Alcohol Depend. 2009;99(1–3):345–349. [PubMed: 18819759]spa
dc.relation.referencesJonas DE, Amick HR, Feltner C; et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: A systematic review and meta-analysis. JAMA. 2014;311(18):1889–1900. [PubMed: 24825644]spa
dc.relation.referencesLópez, G. E. Á., Brindis, F., Niizawa, S. C., & Martínez, R. V. (2014). Cannabis sativa L., una planta singular. Revista Mexicana de Ciencias Farmaceuticas, 45(4).spa
dc.relation.referencesMadras, B. K. (2015). Update of Cannabis and its medical use. Alcohol and Drug Abuse Research, 5(37), 1–41.spa
dc.relation.referencesThabuis C, Tissot-Favre D, Bezelgues JB, Martin JC, Cruz-Hernandez C, Dionisi F, et al. Biological functions and metabolism of oleoylethanolamide. Lipids. 2008;43(10):887–94.spa
dc.relation.referencesAntón M, Alén F, Gómez de Heras R, Serrano A, Pavón FJ, Leza JC, García-Bueno B, Rodríguez de Fonseca F, Orio L. Oleoylethanolamide prevents neuroimmune HMGB1/TLR4/NF-kB danger signaling in rat frontal cortex and depressive-like behavior induced by ethanol binge administration. Addict Biol. 2017 May;22(3):724-741. doi: 10.1111/adb.12365. Epub 2016 Feb 9. PMID: 26857094.spa
dc.relation.referencesOrio L, Alen F, Pavón FJ, Serrano A, García-Bueno B. Oleoylethanolamide,, Neuroinflammation, and Alcohol Abuse. Front Mol Neurosci. 2019 Jan 9;11:490. doi:10.3389/fnmol.2018.00490. PMID: 30687006; PMCID: PMC6333756.spa
dc.relation.referencesSilva-Peña D, Rivera P, Alén F, Vargas A, Rubio L, García-Marchena N, Pavón FJ, Serrano A, Rodríguez de Fonseca F, Suárez J. Oleoylethanolamide Modulates BDNF-ERK Signaling and Neurogenesis in the Hippocampi of Rats Exposed to Δ9-THC and Ethanol Binge Drinking During Adolescence. Front Mol Neurosci. 2019 Apr 24;12:96. doi: 10.3389/fnmol.2019.00096. PMID: 31068789; PMCID: PMC6491684.spa
dc.relation.referencesAntón M, Rodríguez-González A, Rodríguez-Rojo IC, Pastor A, Correas Á, Serrano A, Ballesta A, Alén F, Gómez de Heras R, de la Torre R, Rodríguez de Fonseca F, Orio L. Increased plasma oleoylethanolamide and palmitoleoylethanolamide levels correlate with inflammatory changes in alcohol binge drinkers: the case of HMGB1 in women. Addict Biol. 2018 Nov;23(6):1242-1250. doi: 10.1111/adb.12580. Epub 2017 Nov 27. PMID: 29178411.spa
dc.relation.referencesGalan-Rodriguez B, Suarez J, Gonzalez-Aparicio R, Bermudez-Silva FJ, Maldonado R, Robledo P, Rodriguez de Fonseca F, Fernandez-Espejo E. Oleoylethanolamide exerts partial and dose-dependent neuroprotection of substantia nigra dopamine neurons. Neuropharmacology. 2009 Mar;56(3):653-64. doi: 10.1016/j.neuropharm.2008.11.006. Epub 2008 Dec 7. PMID: 19070629.spa
dc.relation.referencesAhern GP (2003) Activation of TRPV1 by the satiety factor oleoylethanolamide. J Biol Chem 278: 30429–34.spa
dc.relation.referencesBisogno T, Maurelli S, Melck D, Petrocellis L De, Marzo V Di. Biosynthesis , Uptake , and Degradation of Anandamide and Palmitoylethanolamide in Leukocytes *. 1997;272(6):3315–23.spa
dc.relation.referencesNagatsu T, Sawada M (2005) Inflammatory process in Parkinson’s disease: role for cytokines. Curr Pharm Des 11:999–1016 .spa
dc.relation.referencesMunoz AM, Rey P, Parga J, Guerra MJ, Labandeira-Garcia JL (2005) Glial overexpression of heme oxygenase-1: a histochemical marker for early stages of striatal damage. J Chem Neuroanat 29:113–126.spa
dc.relation.referencesRacke M. K., Gocke A. R., Muir M., Diab A., Drew P. D., Lovett-Racke A. E. (2006). Nuclear receptors and autoimmune disease: the potential of PPAR agonists to treat multiple sclerosis. J. Nutr. 136 700–703. 10.1093/jn/136.3.700 .spa
dc.relation.referencesZhou Y., Yang L., Ma A., Zhang X., Li W., Yang W., et al. (2012). Orally administered oleoylethanolamide protects mice from focal cerebral ischemic injury by activating peroxisome proliferator-activated receptor alpha. Neuropharmacology 63 242–249.10.1016/j.neuropharm.2012.03.008spa
dc.relation.referencesMelis M., Pillolla G., Luchicchi A., Muntoni A. L., Yasar S., Goldberg S. R., et al. (2008). Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors. J. Neurosci. 28 13985–13994. 10.1523/JNEUROSCI.3221-08.2008spa
dc.relation.referencesBilbao A., Blanco E., Luque-Rojas M. J., Suárez J., Palomino A., Vida M., et al. (2013). Oleoylethanolamide dose-dependently attenuates cocaine-induced behaviours through a PPARα receptor-independent mechanism. Addict. Biol. 18 78–87.10.1111/adb.12006spa
dc.relation.referencesRodríguez-González A, Vitali F, Moya M, De Filippo C, Passani MB, Orio L. Effects of Alcohol Binge Drinking and Oleoylethanolamide Pretreatment in the Gut Microbiota. Front Cell Infect Microbiol. 2021 Nov 23;11:731910. doi: 10.3389/fcimb.2021.731910. PMID: 34888256; PMCID: PMC8651011.spa
dc.relation.referencesOrio L. The multifaceted potential of the lipid transmitter oleoylethanolamide to treat alcohol-induced neuroinflammation and alcohol use disorders. Neural Regen Res. 2020 Jan;15(1):71-72. doi: 10.4103/1673-5374.264457. PMID: 31535652; PMCID: PMC6862416.spa
dc.relation.referencesSayd A., Antón M., Alén F., Caso J. R., Pavón J., Leza J. C., et al. (2015). Systemic administration of oleoylethanolamide protects from neuroinflammation and anhedonia induced by LPS in rats. Int. J. Neuropsychopharmacol. 18:yu111. 10.1093/ijnp/pyu111spa
dc.relation.referencesGonzalez-Aparicio R, Blanco E, Serrano A, Pavon FJ, Parsons LH, Maldonado R, Robledo P, Fernandez-Espejo E, de Fonseca FR. The systemic administration of oleoylethanolamide exerts neuroprotection of the nigrostriatal system in experimental Parkinsonism. Int J Neuropsychopharmacol. 2014 Mar;17(3):455-68. doi: 10.1017/S1461145713001259. Epub 2013 Oct 29. PMID: 24169105.spa
dc.relation.referencesMock ED, Gagestein B, Stelt M Van Der. Progress in Lipid Research Anandamide and other N -acylethanolamines : A class of signaling lipids with therapeutic opportunities. Prog Lipid Res [Internet]. 2023;89(July 2022):101194. Available from: https://doi.org/10.1016/j.plipres.2022.101194spa
dc.relation.referencesElliot D. Mock, Berend Gagestein, Mario van der Stelt, Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities, Progress in Lipid Research, Volume 89, 2023, 101194, ISSN 0163-7827, https://doi.org/10.1016/j.plipres.2022.101194.spa
dc.relation.referencesWorld Health Organization. Department of Essential Medicines and Health Products, Team of Innovation A and U. Cannabidiol (CBD) Critical Review Report. Expert Comm Drug Depend [Internet]. 2018;(Junio):4–7. Disponible en: https://www.who.int/medicines/access/controlled-substances/WHOCBDReportMay2018-2.pdfspa
dc.relation.referencesChye Y, Christensen E, Solowij N, Yücel M. The endocannabinoid system and cannabidiol’s promise for the treatment of substance use disorder. Front Psychiatry. 2019;10(FEB):1–12.spa
dc.relation.referencesPrus AJ, James JR, Rosecrans JA. Conditioned Place Preference. In: Methods of Behavior Analysis in Neuroscience. 2nd ed. CRC Press/Taylor & Francis, Boca Raton (FL); 2009. PMID: 21204336.spa
dc.relation.referencesKomada M, Takao K, Miyakawa T. Elevated plus maze for mice. J Vis Exp. 2008 Dec 22;(22):1088. doi: 10.3791/1088. PMID: 19229173; PMCID: PMC2762911.spa
dc.relation.referencesE., B. (1969). The Mighty Mouse: The Impact of Rodents on Advances in Biomedical Research. Bmj, 3(5672), 706–706. https://doi.org/10.1136/bmj.3.5672.706.spa
dc.relation.referencesEl pez cebra: una especie modelo - Volumen XXV - Número 1 - Revista: La ciencia y el hombre - Universidad Veracruzana [Internet]. [citado 2022 May 17]. Disponible en: https://www.uv.mx/cienciahombre/revistae/vol25num1/articulos/pez/spa
dc.relation.referencesMoya M, San Felipe D, Ballesta A, Alén F, Rodríguez de Fonseca F, García-Bueno B, Marco EM, Orio L. Cerebellar and cortical TLR4 activation and behavioral impairments in Wernicke-Korsakoff Syndrome: Pharmacological effects of oleoylethanolamide. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jun 8;108:110190. doi: 10.1016/j.pnpbp.2020.110190. Epub 2020 Dec 1. PMID: 33271211.spa
dc.relation.referencesPower analysis for two-group independent sample t-test | G*Power Data Analysis Examples [Internet]. [citado 2022 Agosto 23]. Disponible en: https://stats.oarc.ucla.edu/other/gpower/power-analysis-for-two-group-independent-sample-t-test/spa
dc.relation.referencesErdfelder, E., Faul, F., & Buchner, A. (1996). GPOWER: A general power analysis program. Behavior Research Methods, Instruments & Computers, 28(1), 1–11. https://doi.org/10.3758/BF03203630spa
dc.relation.referencesZineb Ibn Lahmar Andaloussi, Wendy Lauer, Simo S. Zulu, Khalid Taghzouti, Oualid Abboussi, Acute cannabidiol treatment attenuates ethanol-induced place preference and reduces aggressivity in group-housed male rats, Pharmacology Biochemistry and Behavior, Volume 211, 2021, 173290, ISSN 0091-3057, https://doi.org/10.1016/j.pbb.2021.173290.spa
dc.relation.referencesMartín-Sánchez A, Warnault V, Montagud-Romero S, Pastor A, Mondragón N, De La Torre R, et al. Alcohol-induced conditioned place preference is modulated by CB2 cannabinoid receptors and modifies levels of endocannabinoids in the mesocorticolimbic system. Pharmacol Biochem Behav [Internet].spa
dc.relation.referencesde Carvalho CR, Takahashi RN. Cannabidiol disrupts the reconsolidation of contextual drug-associated memories in Wistar rats. Addict Biol. 2017;22(3):742–51 spa
dc.relation.referencesClayman CL, Hwang C, Connaughton VP. Ethanol and caffeine age-dependently alter brain and retinal neurochemical levels without affecting morphology of juvenile and adult zebrafish (Danio rerio). PLoS One. 2023 Jul 5;18(7):e0286596. doi: 10.1371/journal.pone.0286596. PMID: 37405983; PMCID: PMC10321635.spa
dc.relation.referencesTorres OV, Walker EM, Beas BS, O'Dell LE. Female rats display enhanced rewarding effects of ethanol that are hormone dependent. Alcohol Clin Exp Res. 2014 Jan;38(1):108-15. doi: 10.1111/acer.12213. Epub 2013 Aug 1. PMID: 23909760; PMCID: PMC3842413.spa
dc.relation.referencesRamachandra N, Ramesh G. Essentials of Laboratory Animal Science : Principles and Practices.spa
dc.relation.referencesMoctezuma Viera, K. R. (2020). Utilización de animales en la investigación biomédica y médica. Revista Iberoamericana de Bioética, (12), 01–19. https://doi.org/10.14422/rib.i12.y2020.011spa
dc.relation.referencesOPS/OMS PANAFTOSA - OPS/OMS en el Simposio: Disminución del uso de animales en pruebas de control de calidad. (n.d.). Citado Abril 20, 2021, disponible en: https://www.paho.org/panaftosa/index.php?option=com_content&view=article&id=112:ops-oms-en-el-simposio-disminucion-del-uso-de-animales-em-pruebas-de-control-de-calidad&Itemid=504spa
dc.relation.referencesD.O.U.E. DIRECTIVA 2010/63/UE DEL PARLAMENTO EUROPEO Y DEL CONSEJO de 22 de septiembre de 2010 relativa a la protección de los animales utilizados para fines científicos. DOUE. 2010;L 276(20 de octubre de 2010):33–79.spa
dc.relation.referencesCardozo de Martínez, Carmen Alicia, & de Osorio, Afife Mrad. (2008). Ética en investigación con animales: Una actitud responsable y respetuosa del investigador con rigor y calidad científica. Revista Latinoamericana de Bioética, 8(2), 46-71. Citado Diciembre 13, 2021, disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S1657-47022008000200006&lng=en&tlng=esspa
dc.relation.referencesSilver RJ. The endocannabinoid system of animals. Animals. 2019;9(9).spa
dc.relation.referencesViudez Martinez A, García-Gutiérrez MS, Manzanares J. P.735 Acute and chronic dose-response effects of cannabidiol on heavy alcohol drinking in male and female mice. Eur Neuropsychopharmacol [Internet]. 2019;29:S494. Disponible en: https://doi.org/10.1016/j.euroneuro.2019.09.771spa
dc.relation.referencesKnight P, Chellian R, Wilson R, Behnood-Rod A, Panunzio S, Bruijnzeel AW. Sex differences in the elevated plus-maze test and large open field test in adult Wistar rats. Pharmacol Biochem Behav. 2021 May;204:173168. doi: 10.1016/j.pbb.2021.173168. Epub 2021 Mar 5. PMID: 33684454; PMCID: PMC8130853.spa
dc.relation.referencesDi Scala C, Fantini J, Yahi N, Barrantes FJ, Chahinian H. Anandamide Revisited: How Cholesterol and Ceramides Control Receptor-Dependent and Receptor-Independent Signal Transmission Pathways of a Lipid Neurotransmitter. Biomolecules. 2018 May 22;8(2):31. doi: 10.3390/biom8020031. PMID: 29789479; PMCID: PMC6022874.spa
dc.relation.referencesPiomelli D, Scalvini L, Fotio Y, Lodola A, Spadoni G, Tarzia G, Mor M (2020) N-Acylethanolamine Acid Amidase (NAAA): Structure, Function, and Inhibition. J Med Chem 63: 7475–7490.spa
dc.relation.referencesViudez-Martínez A, García-Gutiérrez MS, Manzanares J. Gender differences in the effects of cannabidiol on ethanol binge drinking in mice. Addict Biol. 2020;25(3):1–10.spa
dc.relation.referencesTurna J, Syan SK, Frey BN, Rush B, Costello MJ, Weiss M, et al. Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy: A Systematic Review. Alcohol Clin Exp Res. 2019;43(4):550–63.spa
dc.relation.referencesKandasamy T, Chandrasekar S, Pichaivel M, Pachaiappan S, Muthusamy G. A Review of Zebrafish as an Alternative Animal Model and Its Benefits over Other Animal Models in Various Disease Conditions A Review of Zebrafish as an Alternative Animal Model and Its Benefits over Other Animal Models in Various Disease Conditions. 2022;(December).spa
dc.relation.referencesLopez-Moreno JA, González-Cuevas G, Rodríguez De Fonseca F, Navarro M. Long-lasting increase of alcohol relapse by the cannabinoid receptor agonist WIN 55,212-2 during alcohol deprivation. J Neurosci. 2004;24(38):8245–52.spa
dc.relation.referencesLaksmidewi AAAP, Soejitno A. Endocannabinoid and dopaminergic system: the pas de deux underlying human motivation and behaviors. J Neural Transm [Internet]. 2021;(0123456789). Disponible en: https://doi.org/10.1007/s00702-021-02326-yspa
dc.relation.referencesIntoxicación por drogas. Anales Sis San Navarra [en línea]. 2003, vol.26, suppl.1, pp.99-128. ISSN 1137-6627spa
dc.relation.referencesMogilnicka E, Przewłocka B. Facilitated shock-induced aggression after chronic treatment with antidepressant drugs in the rat. Pharmacol Biochem Behav. 1981;14(2):129–32.spa
dc.relation.referencesKandasamy T, Chandrasekar S, Pichaivel M, Pachaiappan S, Muthusamy G. A Review of Zebrafish as an Alternative Animal Model and Its Benefits over Other Animal Models in Various Disease Conditions A Review of Zebrafish as an Alternative Animal Model and Its Benefits over Other Animal Models in Various Disease Conditions. 2022;(December).spa
dc.relation.referencesGarcia-Marchena N, Pavon FJ, Pastor A, Araos P, Pedraz M, Romero-Sanchiz P, Calado M, Suarez J, Castilla-Ortega E, Orio L, Boronat A, Torrens M, Rubio G, de la Torre R, Rodriguez de Fonseca F, Serrano A. Plasma concentrations of oleoylethanolamide and other acylethanolamides are altered in alcohol-dependent patients: effect t of length of abstinence. Addict Biol. 2017 Sep;22(5):1366-1377. doi: 10.1111/adb.12408. Epub 2016 May 22. PMID: 27212249.spa
dc.relation.referencesFerrer B., Bermúdez-Silva F. J., Bilbao A., Alvarez-Jaimes L., Sanchez-Vera I., Giuffrida A., et al. (2007). Regulation of brain anandamide by acute administration of alcohol. Biochem. J.404 97–104. 10.1042/BJ20061898spa
dc.relation.referencesSullivan SEO, Kendall DA. Immunobiology Cannabinoid activation of peroxisome proliferator-activated receptors: Potential for modulation of inflammatory disease. Immunobiology [Internet]. 2010;215(8):611–6. Disponible en: http://dx.doi.org/10.1016/j.imbio.2009.09.007spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.licenseAtribución-NoComercial-SinDerivadas 4.0 Internacionalspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/spa
dc.subject.ddc610 - Medicina y salud::613 - Salud y seguridad personalspa
dc.subject.ddc610 - Medicina y salud::615 - Farmacología y terapéuticaspa
dc.subject.ddc610 - Medicina y salud::616 - Enfermedadesspa
dc.subject.decsAlcoholismospa
dc.subject.decsAlcoholismeng
dc.subject.decsIntoxicación Alcohólicaspa
dc.subject.decsAlcoholic Intoxicationeng
dc.subject.decsTrastornos Inducidos por Alcoholspa
dc.subject.decsAlcohol-Induced Disorderseng
dc.subject.decsTrastornos Químicamente Inducidosspa
dc.subject.decsChemically-Induced Disorderseng
dc.subject.decsVigilancia en Salud Públicaspa
dc.subject.decsPublic Health Surveillanceeng
dc.subject.decsAnsiedadspa
dc.subject.decsAnxietyeng
dc.subject.proposalOleoylethanolamineeng
dc.subject.proposalEthanoleng
dc.subject.proposalAlcohol Use Disordereng
dc.subject.proposalAnimal Modeleng
dc.subject.proposalRatseng
dc.subject.proposalFemaleeng
dc.subject.proposalOleoiletanolamidaspa
dc.subject.proposalEtanolspa
dc.subject.proposalRatasspa
dc.subject.proposalMujeresspa
dc.subject.proposalWomeneng
dc.titleInfluencia comportamental de la Oleiletanolamida en la dependencia al etanol : un modelo animalspa
dc.title.translatedBehavioral influence of Oleylethanolamide on ethanol dependence : an animal modeleng
dc.typeTrabajo de grado - Maestríaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_bdccspa
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aaspa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/masterThesisspa
dc.type.redcolhttp://purl.org/redcol/resource_type/TMspa
dc.type.versioninfo:eu-repo/semantics/acceptedVersionspa
dcterms.audience.professionaldevelopmentPúblico generalspa
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2spa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
1128480019.2025.pdf
Tamaño:
854.95 KB
Formato:
Adobe Portable Document Format
Descripción:
Tesis de Maestría en Toxicología
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
5.74 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Maestría en Toxicología